- Our combination not only affords T cell-mediated cytotoxicity but also preserves all the effectors of the function of Rituximab.
- Provides Lower Pricing! Since Naked Antibody is Less Sophisticated than Bispeciﬁc Antibody. And by Biosimilar, Price Could be Further Marked Down.
- The exploitation of approved Rituximab whose efficacy, speciﬁcity, and safety have been conﬁrmed in clinics.
To find further information, please mail to firstname.lastname@example.org